{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-016742","form_type":"8-K","ticker":"STIM","cik":"0001227636","company_name":"Neuronetics, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.883528+00:00","generated_at":"2026-06-22T02:58:29.061699+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Neuronetics Q3 revenue $16.5M (+20% YoY); raises FY2022 guidance to $63-64M","bullets":["Q3 revenue $16.5M (+20% YoY); net loss $(7.6)M ($0.28/sh) vs $(8.2)M loss a year ago.","Record US treatment session revenue $11.9M (+16% YoY); NeuroStar system revenue up 51% to $3.9M.","Raised FY2022 revenue guidance to $63-64M from $60-62M; Q4 expected $16-17M.","Received FDA 510(k) clearance for D-Tect MT Accessory; positive TMS coverage policies from CGS and NGS MACs."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-016742","json":"https://secwatch.observer/filing/0001558370-22-016742.json","markdown":"https://secwatch.observer/filing/0001558370-22-016742.md","text":"https://secwatch.observer/filing/0001558370-22-016742.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1227636/000155837022016742/0001558370-22-016742-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1227636/000155837022016742/stim-20221108x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T02:58:29.061699+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"baefbe6cfe25e5083b9845d063141bae918c8e01","claim":"Neuronetics, Inc. reported the three and nine months ended September 30, 2022 results: revenue $16.5 million, net income $(7.6) million, or $(0.28) per share, EPS $(0.28) per share. Guidance raised.","evidence_excerpt":"therapies in the world, today announced its financial and operating results for the third quarter of 2022. Third Quarter 2022 Highlights ● Third quarter 2022 revenue of $16.5 million, represents a 20% increase as compared to the third quarter 2021 ● Achieved record quarterly U.S. treatment session revenue of $11.9 million in the third quarter 2022, compared","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1227636/000155837022016742/0001558370-22-016742-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and nine months ended September 30, 2022"},{"label":"Revenue","value":"$16.5 million"},{"label":"Net income","value":"$(7.6) million, or $(0.28) per share"},{"label":"EPS","value":"$(0.28) per share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}